Published in J Immunol on February 25, 2011
Gene targeting in NOD mouse embryos using zinc-finger nucleases. Diabetes (2013) 1.52
Purinergic signalling and immune cells. Purinergic Signal (2014) 0.94
P2 receptors and immunity. Microbes Infect (2012) 0.93
Looking in the Porphyromonas gingivalis cabinet of curiosities: the microbium, the host and cancer association. Mol Oral Microbiol (2014) 0.90
Corneal epithelium expresses a variant of P2X(7) receptor in health and disease. PLoS One (2011) 0.86
Altered metabolic signature in pre-diabetic NOD mice. PLoS One (2012) 0.83
P2RX7 Purinoceptor: A Therapeutic Target for Ameliorating the Symptoms of Duchenne Muscular Dystrophy. PLoS Med (2015) 0.78
Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J (2006) 8.12
The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol (2009) 7.80
The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science (1996) 7.10
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem (2001) 5.74
The P2X7 receptor: a key player in IL-1 processing and release. J Immunol (2006) 5.35
Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science (1993) 2.85
Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal (2008) 2.27
High sensitivity of CD4+CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. J Immunol (2005) 1.74
Cutting edge: a natural P451L mutation in the cytoplasmic domain impairs the function of the mouse P2X7 receptor. J Immunol (2002) 1.65
Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J (2009) 1.61
NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity (2003) 1.60
Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. J Immunol (1988) 1.49
Ecto-ADP-ribosyltransferases (ARTs): emerging actors in cell communication and signaling. Curr Med Chem (2004) 1.26
Regulation of immune response by P2X7 receptor. Crit Rev Immunol (2006) 1.22
Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway. J Exp Med (2010) 1.13
CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins. J Immunol (2005) 1.12
NAD+ and ATP released from injured cells induce P2X7-dependent shedding of CD62L and externalization of phosphatidylserine by murine T cells. J Immunol (2009) 1.09
Exacerbation of experimental autoimmune encephalomyelitis in P2X7R-/- mice: evidence for loss of apoptotic activity in lymphocytes. J Immunol (2006) 1.09
Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion. J Immunol (2006) 1.06
A new monoclonal antibody detects a developmentally regulated mouse ecto-ADP-ribosyltransferase on T cells: subset distribution, inbred strain variation, and modulation upon T cell activation. J Immunol (1999) 1.01
NAD+ released during inflammation participates in T cell homeostasis by inducing ART2-mediated death of naive T cells in vivo. J Immunol (2007) 1.00
Idd9/11 genetic locus regulates diabetogenic activity of CD4 T-cells in nonobese diabetic (NOD) mice. Diabetes (2008) 0.97
Differential regulation of P2X7 receptor activation by extracellular nicotinamide adenine dinucleotide and ecto-ADP-ribosyltransferases in murine macrophages and T cells. J Immunol (2009) 0.95
Lipopolysaccharide, IFN-gamma, and IFN-beta induce expression of the thiol-sensitive ART2.1 Ecto-ADP-ribosyltransferase in murine macrophages. J Immunol (2007) 0.94
CD38 is required for the peripheral survival of immunotolerogenic CD4+ invariant NK T cells in nonobese diabetic mice. J Immunol (2006) 0.91
A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes. J Autoimmun (2009) 0.91
Metalloprotease-mediated shedding of enzymatically active mouse ecto-ADP-ribosyltransferase ART2.2 upon T cell activation. J Immunol (2000) 0.89
Generation and characterization of ecto-ADP-ribosyltransferase ART2.1/ART2.2-deficient mice. Mol Cell Biol (2002) 0.88
Major histocompatibility complex class I shedding and programmed cell death stimulated through the proinflammatory P2X7 receptor: a candidate susceptibility gene for NOD diabetes. Diabetes (2004) 0.88
NOD x 129.H2(g7) backcross delineates 129S1/SvImJ-derived genomic regions modulating type 1 diabetes development in mice. Diabetes (2009) 0.88
Rapid induction of naive T cell apoptosis by ecto-nicotinamide adenine dinucleotide: requirement for mono(ADP-ribosyl)transferase 2 and a downstream effector. J Immunol (2001) 0.88
T cells of different developmental stages differ in sensitivity to apoptosis induced by extracellular NAD. Dev Immunol (2002) 0.86
CD4+ CD25+ regulatory T cells prevent type 1 diabetes preceded by dendritic cell-dominant invasive insulitis by affecting chemotaxis and local invasiveness of dendritic cells. J Immunol (2010) 0.81
Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet (2007) 5.68
Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A (2003) 3.75
Mouse models of diabetic nephropathy. J Am Soc Nephrol (2009) 3.74
TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell (2006) 2.46
Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res (2002) 2.30
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol (2009) 1.94
Individual nonobese diabetic mice exhibit unique patterns of CD8+ T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J Immunol (2004) 1.86
Cdcs1, a major colitogenic locus in mice, regulates innate and adaptive immune response to enteric bacterial antigens. Gastroenterology (2005) 1.81
Resistance of C57BL/6 mice to amoebiasis is mediated by nonhemopoietic cells but requires hemopoietic IL-10 production. J Immunol (2006) 1.77
NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity (2003) 1.60
Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol (2010) 1.58
HLA-A*0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes. J Immunol (2006) 1.58
The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. Eur J Immunol (2002) 1.50
Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc Natl Acad Sci U S A (2008) 1.49
Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice. Proc Natl Acad Sci U S A (2002) 1.45
By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma. J Exp Med (2003) 1.39
Diet-induced obesity in two C57BL/6 substrains with intact or mutant nicotinamide nucleotide transhydrogenase (Nnt) gene. Obesity (Silver Spring) (2010) 1.38
Extracellular NAD and ATP: Partners in immune cell modulation. Purinergic Signal (2007) 1.26
Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol (2005) 1.26
During the early prediabetic period in NOD mice, the pathogenic CD8(+) T-cell population comprises multiple antigenic specificities. Clin Immunol (2002) 1.24
Hyperglycemia, maturity-onset obesity, and insulin resistance in NONcNZO10/LtJ males, a new mouse model of type 2 diabetes. Am J Physiol Endocrinol Metab (2007) 1.23
Deconstructing and reconstructing obesity-induced diabetes (diabesity) in mice. Diabetes (2002) 1.22
CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med (2004) 1.20
Refined histopathologic scoring system improves power to detect colitis QTL in mice. Mamm Genome (2004) 1.20
New mouse model to study islet transplantation in insulin-dependent diabetes mellitus. Transplantation (2002) 1.17
Four additional mouse crosses improve the lipid QTL landscape and identify Lipg as a QTL gene. J Lipid Res (2009) 1.16
Caspase-1 is not required for type 1 diabetes in the NOD mouse. Diabetes (2004) 1.16
The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice. Immunol Rev (2005) 1.13
In vivo cytotoxicity of insulin-specific CD8+ T-cells in HLA-A*0201 transgenic NOD mice. Diabetes (2007) 1.13
CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins. J Immunol (2005) 1.12
Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. Diabetes (2011) 1.12
Differential levels of diabetogenic stress in two new mouse models of obesity and type 2 diabetes. Diabetes (2004) 1.09
Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion. J Immunol (2006) 1.06
NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. Diabetes (2003) 1.05
B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice. J Immunol (2004) 1.05
Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism. Vascul Pharmacol (2006) 1.04
Islet allograft survival induced by costimulation blockade in NOD mice is controlled by allelic variants of Idd3. Diabetes (2004) 1.04
Mechanisms underlying resistance of pancreatic islets from ALR/Lt mice to cytokine-induced destruction. J Immunol (2005) 1.04
Proteasome inhibition alters glucose-stimulated (pro)insulin secretion and turnover in pancreatic {beta}-cells. J Biol Chem (2005) 1.03
Absence of a reductase, NCB5OR, causes insulin-deficient diabetes. Proc Natl Acad Sci U S A (2004) 1.03
Enhanced pathogenicity of diabetogenic T cells escaping a non-MHC gene-controlled near death experience. J Immunol (2004) 1.01
Genetic and environmental context determines the course of colitis developing in IL-10-deficient mice. Inflamm Bowel Dis (2002) 1.01
Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo. FASEB J (2007) 1.00
Genetic disassociation of autoimmunity and resistance to costimulation blockade-induced transplantation tolerance in nonobese diabetic mice. J Immunol (2003) 1.00
P2X7 receptor-dependent and -independent T cell death is induced by nicotinamide adenine dinucleotide. J Immunol (2005) 1.00
Idd9/11 genetic locus regulates diabetogenic activity of CD4 T-cells in nonobese diabetic (NOD) mice. Diabetes (2008) 0.97
Requirement for both H-2Db and H-2Kd for the induction of diabetes by the promiscuous CD8+ T cell clonotype AI4. J Immunol (2004) 0.96
B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J Immunol (2012) 0.95
Genes within the Idd5 and Idd9/11 diabetes susceptibility loci affect the pathogenic activity of B cells in nonobese diabetic mice. J Immunol (2006) 0.95
A polymorphism in New Zealand inbred mouse strains that inactivates phosphatidylcholine transfer protein. FEBS Lett (2006) 0.94
Cdcs1 a major colitis susceptibility locus in mice; subcongenic analysis reveals genetic complexity. Inflamm Bowel Dis (2010) 0.93
Adenovirus early region 3 antiapoptotic 10.4K, 14.5K, and 14.7K genes decrease the incidence of autoimmune diabetes in NOD mice. Diabetes (2003) 0.92
Genetic analysis of resistance to Type-1 Diabetes in ALR/Lt mice, a NOD-related strain with defenses against autoimmune-mediated diabetogenic stress. Immunogenetics (2003) 0.92
CD38 is required for the peripheral survival of immunotolerogenic CD4+ invariant NK T cells in nonobese diabetic mice. J Immunol (2006) 0.91
A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes. J Autoimmun (2009) 0.91
Islet cell autoimmunity and transplantation tolerance: two distinct mechanisms? Ann N Y Acad Sci (2003) 0.91
"Agouti NOD": identification of a CBA-derived Idd locus on Chromosome 7 and its use for chimera production with NOD embryonic stem cells. Mamm Genome (2005) 0.90
Invasion of the killer B's in type 1 diabetes. Front Biosci (2007) 0.90
Invariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette. Diabetes (2009) 0.90
ADP-ribosylation of membrane proteins: unveiling the secrets of a crucial regulatory mechanism in mammalian cells. Ann Med (2006) 0.90
Adipokine and insulin profiles distinguish diabetogenic and non-diabetogenic obesities in mice. Obesity (Silver Spring) (2007) 0.89
Genetic control of neutrophil superoxide production in diabetes-resistant ALR/Lt mice. Free Radic Biol Med (2002) 0.88
Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes. Diabetes (2005) 0.88
Prevention of "Humanized" diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approach. Diabetes (2011) 0.88
NOD x 129.H2(g7) backcross delineates 129S1/SvImJ-derived genomic regions modulating type 1 diabetes development in mice. Diabetes (2009) 0.88
Subcongenic analysis of genetic basis for impaired development of invariant NKT cells in NOD mice. Immunogenetics (2007) 0.87
mt-Nd2(a) Modifies resistance against autoimmune type 1 diabetes in NOD mice at the level of the pancreatic β-cell. Diabetes (2010) 0.86
Flow cytometric and immunoblot assays for cell surface ADP-ribosylation using a monoclonal antibody specific for ethenoadenosine. Anal Biochem (2003) 0.86
Major histocompatibility complex-linked diabetes susceptibility in NOD/Lt mice: subcongenic analysis localizes a component of Idd16 at the H2-D end of the diabetogenic H2(g7) complex. Diabetes (2005) 0.86
Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: I. Pathophysiological analysis. Diabetes (2005) 0.85
Rapid identification of MHC class I-restricted antigens relevant to autoimmune diabetes using retrogenic T cells. J Immunol Methods (2008) 0.85
Gene expression profiling of leukemic cells and primary thymocytes predicts a signature for apoptotic sensitivity to glucocorticoids. Cancer Cell Int (2007) 0.85
The diabetes-prone NZO/HlLt strain. I. Immunophenotypic comparison to the related NZB/BlNJ and NZW/LacJ strains. Lab Invest (2002) 0.85
Commonalities of genetic resistance to spontaneous autoimmune and free radical--mediated diabetes. Free Radic Biol Med (2008) 0.85
ALS/Lt: a new type 2 diabetes mouse model associated with low free radical scavenging potential. Diabetes (2004) 0.84
Idd loci synergize to prolong islet allograft survival induced by costimulation blockade in NOD mice. Diabetes (2008) 0.84
Comparison of Two New Mouse Models of Polygenic Type 2 Diabetes at the Jackson Laboratory, NONcNZO10Lt/J and TALLYHO/JngJ. J Diabetes Res (2013) 0.84
Contributions of dysregulated energy metabolism to type 2 diabetes development in NZO/H1Lt mice with polygenic obesity. Metabolism (2004) 0.84
Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: II. Immunologic analysis. Diabetes (2006) 0.84